HS
ACAD icon

Haafor (Singapore)’s Acadia Pharmaceuticals ACAD Stock Holding History

Haafor (Singapore)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,616
Closed -$240K – 203
2019
Q4 		$240K Buy
+5,616
New +$244K 0.16% 206

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Haafor (Singapore)'s ACAD Position: Q1 2020 in Review

Haafor (Singapore) sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 5,616 shares — an estimated $240K sold.

Haafor (Singapore) first reported a position in ACAD in Q4 2019 and held it in 1 quarter. The position peaked at $240K in Q4 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • Haafor (Singapore) reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Haafor (Singapore) sold 5,616 Acadia Pharmaceuticals shares in Q1 2020, an estimated $240K.
  • Haafor (Singapore) first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Haafor (Singapore)'s Acadia Pharmaceuticals position peaked at $240K in Q4 2019.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Haafor (Singapore)'s 13F filing for Q1 2020, filed 13 May 2020.